drugset / Trial / NCT04876573
Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Pilot study for evaluating the feasibility, security and efficacy of the use of Cypropheptadine, an antihistaminic and antiserotonin drug, as an adjunct of the standardized treatment in a population of patient who are hospitalized and requiring oxygen therapy for COVID-19.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2021-12-31
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyproheptadine | Small molecule | 4 mg | Oral |
| Subject | Cyproheptadine | Small molecule | 8 mg | Oral |